Determination of hyperforin in mouse brain by high-performance liquid chromatography/tandem mass spectrometry.
Hyperforin is one of the essential active ingredients of St. John's wort extract, which is used as an antidepressant for mild to moderately severe depressions. In vitro and in vivo data as well as several clinical studies and meta analyses have confirmed the pharmacological effect of treatment with hyperforin-containing preparations. However, little is known about the brain availability of hyperforin until now. Accordingly, a highly sensitive and selective LC/MS method for this purpose was developed and validated. This method proved suitable for the determination of hyperforin in mouse brain, after oral administration of hyperforin sodium salt and St. John's wort extract. This method involves liquid-liquid extraction of hyperforin with ethyl acetate followed by separation with rapid reversed-phase high-performance liquid chromatography and tandem mass spectrometry detection using electrospray ionization. Excellent linearity was obtained for the entire calibration range from 0.25 to 10 ng/mL (corresponding to 2.5-100 ng/g brain tissue concentration, calculated with the factor derived from sample processing) with an average coefficient of correlation of 0.9992. The recovery of hyperforin from mouse brain homogenates was between 71.4 and 75.3% with a relative standard deviation of less than 3%. Validation assays for the lower limit of quantitation yielded an accuracy of 5.8%. Intraday accuracy and precision for the developed method were between 4.6 and 10.6% and 4.3-8.4%, respectively, while the interday parameters varied between 6.7 and 12.2% for accuracy and 2.0-5.0% for precision. After the method validation, hyperforin brain levels in mice, treated with 15 mg/kg hyperforin (either as the sodium salt or as 5% St. John's wort extract), were investigated. The average concentration of hyperforin found for the sodium salt group was 28.8+/-10.1 ng/g of brain (n = 8), which was somewhat higher than the hyperforin concentration of 15.8+/-10.9 ng/g of brain (n = 8), determined in the extract-treated group. This method is robust, selective, and highly sensitive and represents an appropriate tool to further prove the occurrence and distribution of hyperforin in mouse brain.
Keller
Jan-Henning
JH
Institute of Pharmaceutical Chemistry, Biocenter, Biocenter, JW Goethe-University, Marie-Curie-Strasse 9, 60439 Frankfurt, Germany.
Karas
Michael
M
Müller
Walter E
WE
Volmer
Dietrich A
DA
Eckert
Gunter P
GP
Tawab
Mona Abdel
MA
Blume
Henning H
HH
Dingermann
Theodor
T
Schubert-Zsilavecz
Manfred
M
D000284:Administration, Oral; D000818:Animals; D001835:Body Weight; D001923:Brain Chemistry; D001643:Bridged Bicyclo Compounds; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D005260:Female; D051379:Mice; D015394:Molecular Structure; D010696:Phloroglucinol / Q000031:analogs & derivatives / Q000737:chemistry; D012680:Sensitivity and Specificity; D021241:Spectrometry, Mass, Electrospray Ionization / Q000295:instrumentation / Q000379:methods*; D013729:Terpenes / Q000008:administration & dosage / Q000032:analysis* / Q000493:pharmacokinetics / Q000494:pharmacology
D001643:Bridged Bicyclo Compounds; D013729:Terpenes; D010696:Phloroglucinol; C001654:hyperforin